U.S. Biotech Stock News

Safety Insurance Group (SAFT) posted a net profit margin of 7.1%, edging ahead of last year’s 6.8%, with EPS showing 16.7% growth for the year. This upbeat result comes despite a longer-term backdrop where average annual earnings have dropped 22.2% over five years. For investors, high-quality earnings, positive profitability trends, and an attractive dividend balance out concerns around continued long-term earnings declines and shares currently trading at $70.37, above fair value...

Tactile Systems Technology (TCMD) posted a net profit margin of 5.8%, edging above last year’s 5.4% and capping five years of earnings growing at a brisk 42.6% annual clip. Looking ahead, analysts expect earnings to climb a further 12.26% per year with revenue growth forecast at 8.9% per year, which is slower than the US market’s 10.5% projection. The setup combines an above-average valuation, a solid record of profitability, and margins that continue to climb. This sets the stage for...

Comstock Resources (CRK) turned profitable over the past five years, boasting average annual earnings growth of 8.6% and posting net profit margins finally in positive territory. Wall Street is sizing up this momentum, with forecasts calling for a massive 74.6% annual earnings growth, which easily outpaces the US market’s expected 16%. Revenue, meanwhile, is projected to rise at 9.8% per year, just a touch behind the US average of 10.5%. See our full analysis for Comstock Resources. Next, we...

RTX announced that its board declared a quarterly cash dividend of 68 cents per share, payable December 11, 2025, to shareholders of record as of November 21, 2025. Alongside this, RTX reported third-quarter adjusted EPS and revenue ahead of forecasts and raised its full-year guidance, reflecting broad-based demand in defense and commercial aerospace. We'll explore how RTX's raised guidance on the back of strong defense and aerospace demand may influence its investment outlook. This...

Rocket Companies recently reported its third-quarter 2025 results, showing revenue of US$1.61 billion compared to US$646.95 million a year earlier, but with a wider net loss of US$123.85 million versus US$22.01 million previously. Despite a substantial increase in revenue, Rocket's bottom line deteriorated, highlighting that higher sales have not yet translated into improved profitability for the company. We'll examine how Rocket's increase in revenue alongside a deepening net loss could...

SOPHiA GENETICS (NasdaqGS:SOPH) is forecast to post annual revenue growth of 17.91%, surpassing the broader US market's expected 10.5% rate. The company has not yet achieved profitability and losses have actually grown at 4% per year for the past five years, with its net profit margin still in negative territory. For investors, the critical narrative is clear: the top-line growth potential stands out, but persistent losses and questions around the path to profitability remain a defining...

Devon Energy (DVN) has recently seen its stock performance fluctuate, capturing the attention of investors interested in the energy sector’s ongoing shifts. The company’s recent returns over the past month and quarter illustrate this ongoing volatility. See our latest analysis for Devon Energy. Devon Energy’s 1-year total shareholder return is down nearly 15%, and momentum has been choppy despite occasional short-term gains. With shares currently at $32.55, the stock’s long-term run remains...

Calm Health’s new partnership with LifeStance Health Group (LFST) makes it easier for users of the Calm Health app to access higher-acuity mental health services, including therapy, psychiatry, and psychological testing. This collaboration is set to widen LifeStance’s reach in digital mental health care and could support increased patient volume and utilization of its clinical services. See our latest analysis for LifeStance Health Group. While LifeStance Health Group’s latest partnership...

Bath & Body Works recently appointed Maly Bernstein as Chief Commercial Officer and Samantha Charleston as Chief Human Resources Officer, effective November 12, 2025, in a move aimed at advancing its ongoing transformation plans. This leadership update brings seasoned expertise in digital and omnichannel retail, as well as large-scale organizational change, directly addressing some of the company’s key operational and market challenges. We’ll now explore how the addition of Bernstein’s...

Greenlight Capital Re (GLRE) remains unprofitable, but the company has narrowed its losses over the last five years at an annual rate of 25.2%. Despite the ongoing challenges to net profit margin, the stock is drawing investor attention thanks to a low Price-To-Sales Ratio of 0.6x versus a peer average of 4.9x and a trading price of $11.95, well below an estimated fair value of $20.06. With risk sentiment steady and no major negative headlines, the current results put the spotlight on...

Xometry (XMTR) remains unprofitable, with net losses rising at an annual rate of 2.3% over the past five years and no meaningful progress on profit margins. Despite persistent losses, revenue is forecast to increase by 14.8% per year, which would outpace the broader US market's 10.5% growth. Earnings are projected to jump 99% annually, with profitability expected within three years. Investors attracted to Xometry's rapid top-line growth and the promise of a turnaround must weigh this optimism...

Bowhead Specialty Holdings (BOW) posted an impressive set of headline numbers, with earnings forecast to grow at 23.5% per year, well above the US market average of 16%, and revenue projected to rise 19.3% annually compared to the broader market’s 10.5%. Net profit margin improved to 10.1% from last year’s 7.6%, signaling a clear strengthening in profitability. With earnings quality described as high and expectations set for robust growth, investors are likely to focus on the company's...

Bioventus (BVS) recently swung to profitability in the past year, despite an average earnings decline of 16.6% per year over the last five years. The bottom line was affected by a non-recurring loss of $17.3 million for the twelve months ending September 27, 2025. Although revenue is forecast to grow at 6.1% annually, this pace trails the broader US market's 10.5% average. Trading at $7.55, the stock sits well below its estimated fair value of $17.96 and also below analyst targets. Its high...

Ingredion (NYSE:INGR) reported a net profit margin of 9.1%, just above last year’s 9%. Over the past five years, the company has delivered robust annual earnings growth of 23.9%. Looking ahead, forecasts point to much slower annual increases of 1.8% for earnings and 2% for revenue, trailing the broader US market averages of 16% and 10.5% respectively. Investors may still find value here, as the stock’s price-to-earnings ratio of 10.5x comes in well below both the peer and industry averages,...

Amprius Technologies (AMPX) has caught investor attention after announcing a strategic partnership with ESAero to bring its advanced silicon-anode batteries to unmanned aerial vehicles. The company also named Ricardo C. Rodriguez as its new CFO, marking operational progress. See our latest analysis for Amprius Technologies. It has certainly been a big year for Amprius Technologies. After a long period out of the spotlight, the stock has staged a dramatic comeback with a 323.08% year-to-date...

Silicon Laboratories (SLAB) remains unprofitable, with losses expanding at an average rate of 17.3% per year over the last five years. Shares currently trade at $126.77, a premium to the estimated fair value of $66.29. The Price-to-Sales ratio stands at 5.6x compared to an industry average of 5.3x. Looking ahead, investors are eyeing the impressive forecast for both revenue and earnings growth, with profitability expected within the next three years. See our full analysis for Silicon...

Driven Brands Holdings (DRVN) remains unprofitable, with losses accelerating at an average rate of 48.1% per year over the past five years. However, analysts expect earnings to grow by 56.02% annually, projecting the company will achieve profitability within the next three years. This outlook stands above market averages. Revenue is forecast to grow 4% per year, which is slower than the 10.5% US market average, but the company’s valuation continues to attract attention as shares trade well...

uniQure (QURE) shares have been on the move recently, drawing renewed attention from investors tracking biotech stocks. Trading activity suggests a sizeable shift in sentiment. This has prompted many to take a fresh look at the company’s valuation and growth outlook. See our latest analysis for uniQure. uniQure’s share price has been exceptionally volatile, with a steep 56.5% loss this week giving back much of its recent surge. Even so, momentum over the longer term remains significant, with...

ADT (ADT) reported a net profit margin of 12.8%, up from 11% the previous year, highlighting a notable improvement in profitability. While the company posted 23.3% earnings growth for the most recent year, this is below its impressive five-year annual average of 67.7%. With shares trading at $8.08, well under the estimated fair value of $19.86, investors are weighing the appeal of rising margins and an attractive valuation against concerns over ADT’s less favorable financial position. See our...

Dave (DAVE) posted a net profit margin of 29.8%, jumping from 12.9% last year, as revenue is projected to grow at 15% annually, outpacing the US market’s 10.5% average. Over the past year, earnings soared 255.6%, far exceeding the company’s already impressive five-year average of 43.4% annual growth. With high-quality earnings, improved margins, and momentum on both the revenue and profit fronts, investors are likely to zero in on these operational gains as a sign of sustained business...

Harley-Davidson (HOG) is facing a challenging road ahead, with the latest filings pointing to a 3.6% annual drop in revenue and a steeper 11.8% annual decline in earnings expected over the next three years. The company’s net profit margin sits at 10.7%, just below last year’s 10.8%, capping off a period where five-year annual earnings growth averaged 7.8% but has now turned negative over the last twelve months. For investors, these results set the stage for tough decisions as attractive value...

Paymentus Holdings (PAY) posted net profit margins of 5.3%, a slight uptick from last year's 5.2%. Over the past five years, earnings have surged at an impressive 57.4% annual rate, but the latest annual earnings growth of 47% fell short of this pace. Looking ahead, analysts expect earnings to grow 28.1% per year and revenue to expand 19.6% annually. Both figures outpace the broader US market, yet shares trade well above DCF-based estimates with a price-to-earnings ratio of 76.1x. See our...

Telesat (TSAT) remains unprofitable, with losses accelerating at an average rate of 54.1% a year over the past five years. Despite the red ink, the company’s revenue is forecast to grow 23.6% annually, outpacing the US market’s 10.5% projection. While top-line expansion is impressive, TSAT’s net profit margin has yet to improve and the company is expected to stay unprofitable for at least the next three years, putting sustained pressure on investor confidence. See our full analysis for...

AdaptHealth (AHCO) recently turned profitable, with its net profit margin shifting notably over the past year. Despite a -16.2% average annual earnings growth over the last five years, forecasts now call for earnings to grow at 23.1% per year, outpacing the broader US market’s 16%. While revenue is expected to rise 7.3% per year in the coming period, which trails the US average, high earnings quality and significant near-term profit growth are clear upside drivers for investors who see value...